About Examworks Group (NYSE:EXAM)
ExamWorks Group, Inc. is a provider of independent medical examinations (IMEs), peer reviews, bill reviews, Medicare compliance, case management and other related services (IME services or the IME industry). The Company conducts its business through four geographic segments, namely, the United States, Canada, the United Kingdom and Australia. The Company provides IME services through its medical panel of credentialed physicians and other medical providers. Its clients include property and casualty insurance carriers, law firms, third-party claim administrators and government agencies that use independent services to confirm the veracity of claims by sick or injured individuals and to facilitate care for workers' compensation, automotive, personal injury liability and disability insurance coverage. The Company also provides a range of services, including Medicare compliance services, bill review services and case management services.
Industry, Sector and Symbol
Industry Ambulance & Emergency Services
Sub-IndustryHealth Care Services
Trailing P/E Ratio233.733333333333
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity3.60%
Return on Assets1.21%
Examworks Group (NYSE:EXAM) Frequently Asked Questions
What is Examworks Group's stock symbol?
Examworks Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "EXAM."
How were Examworks Group's earnings last quarter?
Examworks Group, Inc. (NYSE:EXAM) released its quarterly earnings data on Tuesday, May, 10th. The business services provider reported $0.08 EPS for the quarter, hitting the Zacks' consensus estimate of $0.08. The business services provider earned $226.50 million during the quarter, compared to analysts' expectations of $217.47 million. Examworks Group had a net margin of 1.44% and a return on equity of 3.60%. The company's revenue for the quarter was up 15.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.05 earnings per share. View Examworks Group's Earnings History.
Who are some of Examworks Group's key competitors?
Some companies that are related to Examworks Group include Indivior (INDV), Abcam (ABC), BTG (BTG), NuVasive (NUVA), Dechra Pharmaceuticals (DPH), Press Ganey (PGND), Select Medical (SEM), Halyard Health (HYH), Hikma Pharmaceuticals (HIK), Udg Healthcare (UDG), Primary Health Care (PRY), Aerie Pharmaceuticals (AERI), LifePoint Health (LPNT), Sangamo Therapeutics (SGMO), Auxilium Pharmaceuticals (AUXL), Ignyta (RXDX), Spectranetics (SPNC) and Editas Medicine (EDIT).
How do I buy Examworks Group stock?
Shares of Examworks Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Examworks Group's stock price today?
One share of Examworks Group stock can currently be purchased for approximately $35.06.
How big of a company is Examworks Group?
Examworks Group has a market capitalization of $1.46 billion.
How can I contact Examworks Group?
Examworks Group's mailing address is 3280 Peachtree Rd NE Ste 2625, ATLANTA, GA 30305-2457, United States. The business services provider can be reached via phone at +1-404-9522400.
MarketBeat Community Rating for Examworks Group (EXAM)MarketBeat's community ratings are surveys of what our community members think about Examworks Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Examworks Group (NYSE:EXAM) Earnings History and Estimates Chart
Examworks Group (NYSE EXAM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2016||Q1||$0.08||$0.08||$217.47 million||$226.50 million||View||N/A|
|2/23/2016||Q4||$0.05||$0.10||$199.06 million||$208.50 million||View||Listen|
|11/4/2015||Q3||$0.09||$0.17||$204.53 million||$206.00 million||View||Listen|
|7/28/2015||Q2||($0.10)||($0.19)||$201.70 million||$208.70 million||View||Listen|
|5/5/2015||Q115||$0.05||$0.05||$192.50 million||$196.32 million||View||Listen|
|2/18/2015||Q4 2014||$0.09||$194.67 million||$202.06 million||View||N/A|
|11/4/2014||Q314||$0.06||$0.08||$195.80 million||$204.10 million||View||Listen|
|7/29/2014||Q214||$0.04||$0.09||$184.52 million||$196.45 million||View||Listen|
|5/6/2014||Q114||($0.04)||($0.01)||$166.64 million||$173.00 million||View||Listen|
|2/25/2014||Q413||($0.06)||($0.04)||$151.51 million||$158.80 million||View||Listen|
|10/30/2013||Q3 2013||($0.08)||($0.06)||$151.60 million||$152.35 million||View||N/A|
|7/30/2013||Q2 2013||($0.10)||($0.08)||$151.60 million||$156.10 million||View||Listen|
|5/8/2013||Q1 2013||($0.07)||($0.10)||$145.57 million||$148.70 million||View||Listen|
|2/27/2013||Q4 2012||($0.16)||($0.08)||$135.77 million||$139.64 million||View||Listen|
|11/5/2012||Q312||($0.18)||($0.14)||$127.09 million||$130.10 million||View||N/A|
Examworks Group (NYSE:EXAM) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Examworks Group (NYSE:EXAM)
No dividend announcements for this company have been tracked by MarketBeat.com
Examworks Group (NYSE EXAM) Insider Trading and Institutional Ownership History
Examworks Group (NYSE EXAM) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/6/2016||De Castro Jose Migue Fernandez||CFO||Sell||9,798||$34.80||$340,970.40||50,069|| |
|6/3/2016||Crystal B Patmore||EVP||Sell||2,030||$34.80||$70,644.00||21,043|| |
|6/3/2016||James K Price||CEO||Sell||3,853||$34.81||$134,122.93||544,216|| |
|6/3/2016||Kevin J Kozlowski||Insider||Sell||2,435||$34.80||$84,738.00||30,362|| |
|6/3/2016||Richard E Perlman||Chairman||Sell||3,160||$34.81||$109,999.60||441,684|| |
|6/3/2016||Wesley Campbell||President||Sell||3,247||$34.80||$112,995.60||29,642|| |
|3/9/2016||Crystal B Patmore||EVP||Sell||8,507||$28.47||$242,194.29||29,730|| |
|3/9/2016||Kevin J Kozlowski||Insider||Sell||5,106||$28.47||$145,367.82||36,793|| |
|3/9/2016||Wesley Campbell||President||Sell||6,805||$28.47||$193,738.35||38,214|| |
|12/9/2015||J Thomas Presby||Director||Buy||4,000||$26.90||$107,600.00||71,886|| |
|9/4/2015||Richard E. Perlman||Chairman||Sell||247,217||$34.16||$8,444,932.72||432,304|| |
|9/2/2015||Crystal B. Patmore||EVP||Sell||85,084||$34.87||$2,966,879.08||27,400|| |
|9/2/2015||Kevin J. Kozlowski||insider||Sell||70,000||$34.36||$2,405,200.00||32,883|| |
|9/1/2015||Clare Arguedas||EVP||Sell||10,222||$35.03||$358,076.66||21,746|| |
|9/1/2015||Wesley Campbell||President||Sell||71,010||$35.02||$2,486,770.20||43,837|| |
|6/15/2015||William A Shutzer||Director||Sell||16,464||$40.18||$661,523.52|| |
|6/4/2015||J Thomas Presby||Director||Sell||20,000||$39.44||$788,800.00|| |
|6/3/2015||William A Shutzer||Director||Sell||3,100||$40.00||$124,000.00|| |
|6/1/2015||William A Shutzer||Director||Sell||16,900||$41.12||$694,928.00|| |
|5/7/2015||J Thomas Presby||Director||Sell||25,000||$41.56||$1,039,000.00|| |
|3/9/2015||Crystal B Patmore||EVP||Sell||3,295||$39.82||$131,206.90|| |
|3/9/2015||De Castro Jose Migue Fernandez||CFO||Sell||4,948||$39.81||$196,979.88|| |
|3/9/2015||Kevin J Kozlowski||Insider||Sell||3,960||$39.67||$157,093.20|| |
|3/9/2015||Wesley Campbell||President||Sell||5,278||$39.66||$209,325.48|| |
|5/13/2014||Crystal Patmore||EVP||Sell||119,460||$32.30||$3,858,558.00||20,496|| |
|5/13/2014||De Castro Jose Migue Fernandez||CFO||Sell||207,440||$32.30||$6,700,312.00||43,247|| |
|5/13/2014||James Price||CEO||Sell||814,897||$32.30||$26,321,173.10||471,235|| |
|5/13/2014||Kevin Kozlowski||Insider||Sell||126,686||$32.30||$4,091,957.80||24,605|| |
|5/13/2014||Richard Perlman||Chairman||Sell||939,025||$32.30||$30,330,507.50||647,827|| |
|5/13/2014||Wesley Campbell||President||Sell||121,086||$32.30||$3,911,077.80||32,796|| |
|5/13/2014||William Shutzer||Director||Sell||474,567||$32.30||$15,328,514.10||365,613|| |
|8/2/2013||Clare Arguedas||EVP||Sell||46,027||$24.02||$1,105,568.54|| |
|8/2/2013||Kevin J Kozlowski||Insider||Sell||60,000||$23.69||$1,421,400.00|| |
|8/2/2013||Wesley Campbell||President||Sell||65,000||$23.87||$1,551,550.00|| |
|6/3/2013||De Castro Jose Migue Fernandez||CFO||Buy||2,500||$18.85||$47,125.00|| |
|6/3/2013||James K Price||CEO||Buy||11,000||$18.92||$208,120.00|| |
|5/13/2013||Wesley Campbell||President||Sell||50,000||$18.25||$912,500.00|| |
|3/4/2013||Richard E Perlman||Chairman||Buy||14,500||$14.30||$207,350.00|| |
|3/1/2013||James K Price||CEO||Buy||14,500||$13.97||$202,565.00|| |
|11/14/2012||De Castro Jose Migue Fernandez||CFO||Buy||5,000||$11.48||$57,400.00|| |
|11/14/2012||James K Price||CEO||Buy||18,000||$11.51||$207,180.00|| |
Examworks Group (NYSE EXAM) News Headlines
|Critical Survey: Examworks Group (EXAM) versus Accretive Health (RCM)|
www.americanbankingnews.com - November 29 at 7:30 AM
|Analyzing Accretive Health (RCM) and Examworks Group (EXAM)|
www.americanbankingnews.com - November 26 at 11:20 AM
|Comparing Examworks Group (EXAM) & Accretive Health (RCM)|
www.americanbankingnews.com - November 23 at 1:28 PM
|Accretive Health (RCM) versus Examworks Group (EXAM) Financial Review|
www.americanbankingnews.com - November 19 at 11:54 AM
|Reviewing Examworks Group (EXAM) & Accretive Health (RCM)|
www.americanbankingnews.com - November 17 at 5:06 PM
|Contrasting Examworks Group (EXAM) and Accretive Health (RCM)|
www.americanbankingnews.com - November 15 at 11:52 PM
|Examworks Group, Inc. Company Profile|
biz.yahoo.com - January 29 at 10:10 PM
|EXAMWORKS GROUP, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or|
biz.yahoo.com - July 27 at 9:59 AM
|EXAMWORKS GROUP, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - July 26 at 12:25 PM
|Deals of the Day: Opportunity in U.K., Lawyers in the Line of Fire|
blogs.wsj.com - July 13 at 5:13 PM
|EXAMWORKS GROUP, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal|
biz.yahoo.com - June 29 at 8:34 AM
|ExamWorks Announces Conditional Redemption of All $500 Million 5.625% Senior Notes Due 2023|
www.nasdaq.com - June 24 at 5:00 PM
|ExamWorks Group, Inc. -- Moody's assigns B2 CFR and B1 credit facilities ratings to ExamWorks Group; outlook stable|
www.moodys.com - June 8 at 4:49 PM
|United Technologies' (UTX) Otis Wins Cruise Ship Contract|
www.zacks.com - June 7 at 5:03 PM
|EXAMWORKS GROUP, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - June 2 at 9:20 AM
Examworks Group (NYSE:EXAM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Examworks Group (NYSE:EXAM) Income Statement, Balance Sheet and Cash Flow Statement
Examworks Group (NYSE EXAM) Stock Chart for Thursday, February, 22, 2018